Vedolizumab

The safety profile of Entyvio remained favorable through 8 years of use in patients with inflammatory bowel disease, according to results from the GEMINI long-term safety study.

Treatment with Stelara was associated with superior outcomes in patients with Crohn’s disease who previously failed anti-TNF therapy, according to study results.

For some patients with inflammatory bowel disease, treatments can be ineffective, and in patients where they do work, they do not always last.

Inflammatory bowel disease is a debilitating condition that takes a lifetime of treatment to control. Over the years, medical therapies for the disease have evolved greatly, but the approval of anti-tumor necrosis factor alpha therapy for the treatment of Crohn’s disease in 1998 was a turning point in IBD treatment management.